Imperial College London
Portrait Picture

ProfessorJenniferQuint

Faculty of Medicine, School of Public Health

Professor of Respiratory Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 8821j.quint

 
 
//

Location

 

.922Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{campbell:2019:10.1186/s13601-019-0256-9,
author = {campbell, J and perry, R and papadopoulos, N and krishnan, J and brusselle, G and chisholm, A and bjermer, L and thomas, M and van, ganse E and van, den berge M and Quint, J and price, D and roche, N},
doi = {10.1186/s13601-019-0256-9},
journal = {Clinical and Translational Allergy},
title = {The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies},
url = {http://dx.doi.org/10.1186/s13601-019-0256-9},
volume = {9},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundEvidence from observational comparative effectiveness research (CER) is ranked below that from randomized controlled trials in traditional evidence hierarchies. However, asthma observational CER studies represent an important complementary evidence source answering different research questions and are particularly valuable in guiding clinical decision making in real-life patient and practice settings. Tools are required to assist in quality appraisal of observational CER to enable identification of and confidence in high-quality CER evidence to inform guideline development.MethodsThe REal Life EVidence AssessmeNt Tool (RELEVANT) was developed through a step-wise approach. We conducted an iterative refinement of the tool based on Task Force member expertise and feedback from pilot testing the tool until reaching adequate inter-rater agreement percentages. Two distinct pilots were conducted—the first involving six members of the Respiratory Effectiveness Group (REG) and European Academy of Allergy and Clinical Immunology (EAACI) joint Task Force for quality appraisal of observational asthma CER; the second involving 22 members of REG and EAACI membership. The final tool consists of 21 quality sub-items distributed across seven methodology domains: Background, Design, Measures, Analysis, Results, Discussion/Interpretation, and Conflict of Interest. Eleven of these sub-items are considered critical and named “primary sub-items”.ResultsFollowing the second pilot, RELEVANT showed inter-rater agreement ≥ 70% for 94% of all primary and 93% for all secondary sub-items tested across three rater groups. For observational CER to be classified as sufficiently high quality for future guideline consideration, all RELEVANT primary sub-items must be fulfilled. The ten secondary sub-items further qualify the relative strengths and weaknesses of the published CER evidence. RELEVANT could also be applicable to general quality appraisal of observati
AU  - campbell,J
AU  - perry,R
AU  - papadopoulos,N
AU  - krishnan,J
AU  - brusselle,G
AU  - chisholm,A
AU  - bjermer,L
AU  - thomas,M
AU  - van,ganse E
AU  - van,den berge M
AU  - Quint,J
AU  - price,D
AU  - roche,N
DO  - 10.1186/s13601-019-0256-9
PY  - 2019///
SN  - 2045-7022
TI  - The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies
T2  - Clinical and Translational Allergy
UR  - http://dx.doi.org/10.1186/s13601-019-0256-9
UR  - http://hdl.handle.net/10044/1/68060
VL  - 9
ER  -
Download